Ireland
--:--IST
Starting soon Observational

Artificial Intelligence For Outcomes Research in Crohn's Disease: Digital Pathology Assessment of Fibrosis and Association With Patient History and Clinical Outcomes

NCT07795476 · tracked via the Priya Life Science Spain tracker
Sponsor
PharmaNest, Inc
Phase
Observational
Started
2026-11-01
Last updated
2026-10-01

Condition(s) studied

Crohn DiseaseFibrostenotic Crohn's DiseaseCD - Crohn's Disease

Investigational drug(s) / intervention(s)

Ph-FCS(Muc) fibrosis severity Digital Pathology biomarker

Ph-FCS(Muc) fibrosis severity Digital Pathology biomarker: Ph-FCS(Muc) is a continuous, quantitative digital pathology biomarker that integrates multiple histological features of mucosal fibrosis into a single fibrosis severity score, providing a more granular assessment than conventional ordinal histological staging.

Study summary

The goal of this retrospective observational study is to learn whether artificial intelligence-based digital pathology can measure intestinal fibrosis and help identify patients with Crohn's disease who may be at greater risk of disease progression and surgery.

The main questions the study aims to answer are:

Does the FibroNest Phenotypic Fibrosis Composite Score \[Ph-FCS(Muc)\], measured from routinely collected ileal biopsies, reflect the severity of fibrosis assessed by a pathologist?

* Is Ph-FCS(Muc) associated with Crohn's disease characteristics and history?
* Can Ph-FCS(Muc) help predict whether a patient will subsequently require a first ileal surgical resection for fibrostenotic Crohn's disease?

Researchers will retrospectively analyze previously collected ileal biopsies and medical information from adults with Crohn's disease. Biopsy slides will be digitized and analyzed using FibroNest digital pathology, and the resulting fibrosis measurements will be compared with pathologist assessments, clinical characteristics, disease history, and subsequent clinical outcomes.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Adult pts (\>=18 years old) diagnosed with Crohn's disease based on Investigator's assessment. * Ileal biopsy with fibrosis Masson's Trichome staining available for digitization or already digitized at 40X ( or \~0.25micron per pixel) * The cohort will contain patients with various levels of intensity and distribution of fibrosis as defined by the pathologist with a minimum of 7 patients for any level of intensity and distribution for being required. * Minimum information available for each patient (see Appendix 2, table 1) Exclusion Criteria: * History of gastrointestinal endoscopic interventions and/or surgery for Crohn's disease management such as endoscopic balloon dilation, strictureplasty, stricturectomy or bowel resection prior to the index biopsy. * History of gastrointestinal surgery for any indication

Primary outcome measure(s)

  • Occurrence of the First ileal surgical resection for ileal fibro-stenotic Crohn's — 24 months
    Occurrence (and date of occurrence) of the First ileal surgical resection for ileal fibro-stenotic Crohn's , and No endoscopic procedure (balloon dilation, strictureplasty or stricturectomy)

Trial sites (2)

FacilityCityRegionStatus
University Hospital Virgen del Rocio Seville Andalusia
University Hosptal Virgen Macarena Seville Spain
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07795476 on ClinicalTrials.gov ↗ ← All trials in Spain